Treatment and outcome of myocardial infarction in hospitals with and without invasive capability
William J. Rogers, MD, FACC*,
John G. Canto, MD, MSPH, FACC*,
Hal V. Barron, MD, FACC  ,
Joseph A. Boscarino, PhD, MPH ,
David A. Shoultz, PhD|| ¶,
Nathan R. Every, MD, MPH, FACC|| for the Investigators in the National Registry of Myocardial Infarction 2#
* University of Alabama Medical Center, Birmingham, Alabama, USA
University of California, San Francisco Medical Center, San Francisco, California, USA
Genentech, Inc., South San Francisco, California, USA
Merck-Medco Managed Care, Montvale, New Jersey, USA
|| University of Washington, Seattle, Washington, USA
¶ STATPROBE, Inc., Seattle, Washington, USA
# A complete listing of participating registry hospitals is available from STATPROBE, Inc., Lexington, Kentucky, USA
View larger version (17K):
[in a new window]
|
Figure 1 Distribution of hospital types. Most hospitals in the registry had capability to perform coronary angiography (Cath-capable), angioplasty (PTCA-capable) or bypass surgery (CABG-capable). CABG = coronary artery bypass grafting; PTCA = percutaneous transluminal coronary angioplasty.
|
|
View larger version (21K):
[in a new window]
|
Figure 2 Type of acute reperfusion used in the different types of hospitals. Intravenous thrombolytic therapy was the most common reperfusion modality employed, even in hospitals equipped to perform invasive procedures such as IC lytic therapy, PTCA or CABG. CABG = coronary artery bypass grafting; IC lytic = intracoronary administration of thrombolytic; IV lytic = intravenous thrombolytic therapy; PTCA = percutaneous transluminal coronary angioplasty. Unshaded area = IV lytic; Shaded area = invasive: primary PTCA, immediate CABG or IC lytic.
|
|
|
